NEW YORK, Feb 21 – Zygogen of Atlanta, Ga. will provide Curis with its proprietary transgenic zebrafish technology for use in drug discovery, Zygogen said Wednesday.
Zebrafish are similar to knockout mice in that they can serve as model organisms for finding genome-based drug targets, but they offer the advantage of being faster to breed and less expensive.
Zygogen, founded in 1999, uses Z-Tag, a technology through which it can design transgenic zebrafish with organs that are labeled and cell lineages that are delineated.
"We are pleased to provide Curis with access to Zygogen's zebrafish technology," said Nina Sawczuk, Zygogen’s CEO. "We are confident that our technology will accelerate their drug screening programs."
This agreement follows closely after the Sanger Center’s announcement it would begin sequencing the full genome of the zebrafish. Other companies, such as Artemis pharmaceuticals of Tubingen, Germany, are also seeking to commercialize zebrafish technology for use in genomic-based drug response studies.